140 related articles for article (PubMed ID: 31028057)
41. Inhibitory effects of continuous ingestion of Schisandrin A on CYP3A in the rat.
Li WL; Xin HW; Su MW
Basic Clin Pharmacol Toxicol; 2012 Feb; 110(2):187-92. PubMed ID: 21895978
[TBL] [Abstract][Full Text] [Related]
42. Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism.
Thummel KE; O'Shea D; Paine MF; Shen DD; Kunze KL; Perkins JD; Wilkinson GR
Clin Pharmacol Ther; 1996 May; 59(5):491-502. PubMed ID: 8646820
[TBL] [Abstract][Full Text] [Related]
43. Drug-drug interactions and metabolism in cytochrome P450 2C knockout mice: application to troleandomycin and midazolam.
Grimsley A; Gallagher R; Hutchison M; Pickup K; Wilson ID; Samuelsson K
Biochem Pharmacol; 2013 Aug; 86(4):529-38. PubMed ID: 23732297
[TBL] [Abstract][Full Text] [Related]
44. Single-point sampling for assessment of constitutive, induced, and inhibited cytochrome P450 3A activity with alfentanil or midazolam.
Chaobal HN; Kharasch ED
Clin Pharmacol Ther; 2005 Nov; 78(5):529-39. PubMed ID: 16321619
[TBL] [Abstract][Full Text] [Related]
45. HIV protease inhibitors, saquinavir, indinavir and ritonavir: inhibition of CYP3A4-mediated metabolism of testosterone and benzoxazinorifamycin, KRM-1648, in human liver microsomes.
Inaba T; Fischer NE; Riddick DS; Stewart DJ; Hidaka T
Toxicol Lett; 1997 Dec; 93(2-3):215-9. PubMed ID: 9486958
[TBL] [Abstract][Full Text] [Related]
46. Sorafenib and sunitinib, two anticancer drugs, inhibit CYP3A4-mediated and activate CY3A5-mediated midazolam 1'-hydroxylation.
Sugiyama M; Fujita K; Murayama N; Akiyama Y; Yamazaki H; Sasaki Y
Drug Metab Dispos; 2011 May; 39(5):757-62. PubMed ID: 21266595
[TBL] [Abstract][Full Text] [Related]
47. Role of cytochrome P450 3A4 in human metabolism of MK-639, a potent human immunodeficiency virus protease inhibitor.
Chiba M; Hensleigh M; Nishime JA; Balani SK; Lin JH
Drug Metab Dispos; 1996 Mar; 24(3):307-14. PubMed ID: 8820421
[TBL] [Abstract][Full Text] [Related]
48. Time-dependent inhibitory effects of (1R,9S,12S,13R,14S,17R,18E,21S,23S,24R,25S,27R)-1,14-dihydroxy-12-(E)-2-[(1R,3R,4R)-4-hydroxy-3-methoxycyclohexyl]-1-methylvinyl-23,25-dimethoxy-13,19,21,27-tetramethyl-17-(2-oxopropyl)-11,28-dioxa-4-azatricyclo[22.3.1.0(4.9)]octacos-18-ene-2,3,10,16-tetrone (FK1706), a novel nonimmunosuppressive immunophilin ligand, on CYP3A4/5 activity in humans in vivo and in vitro.
Minematsu T; Lee J; Zha J; Moy S; Kowalski D; Hori K; Ishibashi K; Usui T; Kamimura H
Drug Metab Dispos; 2010 Feb; 38(2):249-59. PubMed ID: 19889885
[TBL] [Abstract][Full Text] [Related]
49. The effect of ticagrelor on the metabolism of midazolam in healthy volunteers.
Teng R; Butler K
Clin Ther; 2013 Jul; 35(7):1025-37. PubMed ID: 23870610
[TBL] [Abstract][Full Text] [Related]
50. Meclizine, a pregnane X receptor agonist, is a direct inhibitor and mechanism-based inactivator of human cytochrome P450 3A.
Foo WY; Tay HY; Chan EC; Lau AJ
Biochem Pharmacol; 2015 Oct; 97(3):320-30. PubMed ID: 26239802
[TBL] [Abstract][Full Text] [Related]
51. Species differences in the pharmacokinetics and metabolism of indinavir, a potent human immunodeficiency virus protease inhibitor.
Lin JH; Chiba M; Balani SK; Chen IW; Kwei GY; Vastag KJ; Nishime JA
Drug Metab Dispos; 1996 Oct; 24(10):1111-20. PubMed ID: 8894513
[TBL] [Abstract][Full Text] [Related]
52. Evaluation of the effects of hydrophilic organic solvents on CYP3A-mediated drug-drug interaction in vitro.
Iwase M; Kurata N; Ehana R; Nishimura Y; Masamoto T; Yasuhara H
Hum Exp Toxicol; 2006 Dec; 25(12):715-21. PubMed ID: 17286149
[TBL] [Abstract][Full Text] [Related]
53. Predictions of metabolic drug-drug interactions using physiologically based modelling: Two cytochrome P450 3A4 substrates coadministered with ketoconazole or verapamil.
Perdaems N; Blasco H; Vinson C; Chenel M; Whalley S; Cazade F; Bouzom F
Clin Pharmacokinet; 2010 Apr; 49(4):239-58. PubMed ID: 20214408
[TBL] [Abstract][Full Text] [Related]
54. Conflicting alterations in hepatic expression of CYP3A and enzyme kinetics in rats exposed to 5-fluorouracil: relevance to pharmacokinetics of midazolam.
Fukuno S; Nagai K; Fujiike M; Sasaki Y; Konishi H
Xenobiotica; 2019 Dec; 49(12):1470-1477. PubMed ID: 30714842
[TBL] [Abstract][Full Text] [Related]
55. Quantitative prediction of macrolide drug-drug interaction potential from in vitro studies using testosterone as the human cytochrome P4503A substrate.
Polasek TM; Miners JO
Eur J Clin Pharmacol; 2006 Mar; 62(3):203-8. PubMed ID: 16416302
[TBL] [Abstract][Full Text] [Related]
56. In vivo effect of Schisandrin B on cytochrome P450 enzyme activity.
Li WL; Xin HW; Yu AR; Wu XC
Phytomedicine; 2013 Jun; 20(8-9):760-5. PubMed ID: 23523258
[TBL] [Abstract][Full Text] [Related]
57. Optimization of drug-drug interaction study design: comparison of minimal physiologically based pharmacokinetic models on prediction of CYP3A inhibition by ketoconazole.
Han B; Mao J; Chien JY; Hall SD
Drug Metab Dispos; 2013 Jul; 41(7):1329-38. PubMed ID: 23584886
[TBL] [Abstract][Full Text] [Related]
58. The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin.
Gorski JC; Jones DR; Haehner-Daniels BD; Hamman MA; O'Mara EM; Hall SD
Clin Pharmacol Ther; 1998 Aug; 64(2):133-43. PubMed ID: 9728893
[TBL] [Abstract][Full Text] [Related]
59. Drug-metabolizing enzyme inhibition by ketoconazole does not reduce interindividual variability of CYP3A activity as measured by oral midazolam.
Chen M; Nafziger AN; Bertino JS
Drug Metab Dispos; 2006 Dec; 34(12):2079-82. PubMed ID: 16997909
[TBL] [Abstract][Full Text] [Related]
60. Selective biotransformation of the human immunodeficiency virus protease inhibitor saquinavir by human small-intestinal cytochrome P4503A4: potential contribution to high first-pass metabolism.
Fitzsimmons ME; Collins JM
Drug Metab Dispos; 1997 Feb; 25(2):256-66. PubMed ID: 9029057
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]